Photodynamic Therapy as Palliative Therapy for Invasive Syringoid Eccrine Carcinoma of the Auricle: A Case Report

Claudia Gutiérrez Gómez, Anail Alvarez, Ana Lilia Ruelas, Ixchel Landgrave, Alfonso Vallarta, Laura Andrade

Department of Plastic and Reconstructive Surgery, Medica Sur Hospital, México City, México.
Dermatology Department, Medica Sur Hospital, México City, México.
Plastic Surgery Department, Medica Sur Hospital, México City, México.

DOI: 10.4236/jct.2013.46125                

Abstract

Recurrent eccrine syringomatous carcinoma is an extremely rare adnexal tumor predominantly found in the head and neck region. We present a case of a 75-year-old woman with a 7-year history of recurrent syringoid eccrine carcinoma in the scalp and auricle. She had undergone five previous oncologic resections and declined further oncologic ablation of the auricle, including temporal bone and external ear canal resection. We performed five sessions of palliative photodynamic therapy using topical aminolevulinic acid HCL 20% (ALA) and between 25 and 33 pulses of Intense Pulsed Light (Quantum) with an intensity of 30 Joules. The ALA incubation time was 3 hours, while the time between each session was 4 weeks. This treatment helped to control ulceration, pain, and swelling. We saw the patient 1 month after the last treatment, by that time she moved and we lost contact.

Keywords

Syringoid Eccrine Carcinoma; Photodynamic Therapy

Conflicts of Interest

The authors declare no conflicts of interest.

References

[1]	R. G. Freeman, M. D. Houston and R. K. Winkelmann, “Basal Cell Tumor with Eccrine Differentiation (Eccrine Epitelioma),” JAMA Dermatology, Vol. 100, No. 2, 1969, pp. 234-242. doi:10.1001/archderm.1969.01610260110021
[2]	D. Elder, R. Elenistas and B. D. Ragsdale, “Syringoid Eccrine Carcinoma,” In: F. Lever and G. SchaumburgLever, Eds., Histopathology of the Skin, 8th Edition, Lippincott-Raven, Philadelphia, 1977, pp. 792-793.
[3]	D. J. Cruz, “Sweat Gland Carcinomas: A Comprehensive Review,” Seminars in Diagnostic Pathology, Vol. 4, No. 1, 1987, pp. 38-74.
[4]	L. Hirsh, H. Enterline, E. Rosato, et al., “Sweat Gland Carcinoma,” Annals of Surgery, Vol. 174, 1971, pp. 283-286. doi:10.1097/00000658-197108000-00015
[5]	J. A. Chambers, A. H. Lipschitz, D. Petrisor, C. A. GarcíaMitchel and S. Stepenaskie-Wolz, “Sweat Gland Carcinoma,” Plastic and Reconstructive Surgery, Vol. 123, No. 1, 2009, pp. 33e-35e. doi:10.1097/PRS.0b013e31819056cc
[6]	J. W. Nash, T. L. Barrett, M. Kies, et al., “Metastatic Hidradenocarcinoma with Demonstration of Her-2/Neu Gene Amplification by Fluorescence in Situ Hybridization: Potential Treatment Implications,” Journal of Cutaneous Pathology, Vol. 34, No. 1, 2007, pp. 49-54. doi:10.1111/j.1600-0560.2006.00570.x
[7]	G. Serrano, A. Aliaga, J. Bonillo, et al., “Basal Cell Tumor with Eccrine Differentiation (Eccrine Epithelioma),” Journal of Cutaneous Pathology, Vol. 11, No. 6, 1984, pp. 553-557. doi:10.1111/j.1600-0560.1984.tb00418.x
[8]	E. Hernández-Pérez and R. Cestoni-Parducci, “Nodular Hidradenoma and Hidradenocarcinoma: A 10-Year Review,” Journal of the American Academy of Dermatology, Vol. 12, No. 1, 1985, pp. 15-20. doi:10.1016/S0190-9622(85)70002-3
[9]	A. H. Mehregan, K. Hasimoto and H. Rahbari, “Eccrine Adenocarcinoma: A Clinicopathologic Study of 35 Cases,” Archives of Dermatology, Vol. 119, No. 2, 1983, pp. 104-114. doi:10.1001/archderm.1983.01650260012008
[10]	E. S. Yus, L. R. Caballeo, I. G. Salazar, et al., “Clear Cell Syringoid Carcinoma,” The American Journal of Dermatopathology, Vol. 9, No. 3, 1987, pp. 225-231. doi:10.1097/00000372-198706000-00008
[11]	A. T. Evans, D. M. Parham and L. J. A. Van Niekerk, “Metastasising Eccrine Syringomatous Carcinoma,” Histopathology, Vol. 26, No. 2, 1995, pp. 185-187. doi:10.1111/j.1365-2559.1995.tb00651.x
[12]	R. L. Moy, J. E. Rivkin, H. Lee, et al., “Syringoid Eccrine Carcinoma,” Journal of the American Academy of Dermatology, Vol. 24, No. 5, 1991, pp. 864-867.
[13]	M. Malmusi and G. Collina, “Syringoid Eccrine Carcinoma: A Case Report,” American Journal of Dermatopathology, Vol. 19, No. 5, 1997, pp. 533-535. doi:10.1097/00000372-199710000-00108
[14]	S. W. Dahill and M. Seywright, “Synchronous Occurrence of Cutaneous Lymphadenoma and Syringoid Eccrine Carcinoma in a Single Patient,” Histopathology, Vol. 33, No. 1, 1998, pp. 87-94.
[15]	D. Ramos, C, Monteagudo, C, Carda, et al., “Clear Cell Syringoid Carcinoma,” American Journal of Dermatopathology, Vol. 22, No. 1, 2000, pp. 60-64. doi:10.1097/00000372-200002000-00012
[16]	T. Gregurek-Novak, J. Talan-Hranilovic, N. Troskot, et al., “Syringoid Eccrine Carcinoma,” Journal of the European Academy of Dermatology and Venereology, Vol. 15, No. 2, 2001, pp. 143-146. doi:10.1046/j.1468-3083.2001.00210.x
[17]	T. Ohnishi, S. Kaneko, M. Egi, et al., “Syringoid Eccrine Carcinoma,” American Journal of Dermatopathology, Vol. 24, No. 5, 2002, pp. 409-413. doi:10.1097/00000372-200210000-00007
[18]	P. H. McKee, C. D. M. Fletcher and S. A. Rasbridge, “The Enigmatic Eccrine Epithelioma (eccrine Syringomatous Carcinoma),” American Journal of Dermatopathology, Vol. 12, No. 6, 1990, pp. 552-561. doi:10.1097/00000372-199012000-00004
[19]	W. I. Cottel, “Eccrine Epithelioma: Case Report,” Journal of Dermatologic Surgery & Oncology, Vol. 8, No. 7, 1982, pp. 610-611. doi:10.1111/j.1524-4725.1982.tb00319.x
[20]	C. W. Hanke and R. K. Temofeew, “Basal Cell Carcinoma with Eccrine Differentiation (Eccrine Epithelioma),” Journal of Dermatologic Surgery & Oncology, Vol. 12, No. 8, 1986, pp. 820-824. doi:10.1111/j.1524-4725.1986.tb01988.x
[21]	D. B. Cabbabe, “Eccrine Gland Adenocarcinoma of the Chin,” Plastic & Reconstructive Surgery, Vol. 69, No. 3, 1982, pp. 521-523. doi:10.1097/00006534-198203000-00020
[22]	R. Whittington, M. E. Browning, G. R. Farrell, et al., “Radiation Therapy and Chemotherapy in Malignant Sweat Gland Tumors,” Journal of the American Academy of Dermatology, Vol. 15, No. 5, 1986, pp. 1093-1097. doi:10.1016/S0190-9622(86)70271-5
[23]	P. Piedbois, J. L. Breau, J. F. Morere, et al., “Sweat Gland Carcinoma with Bone and Visceral Metastases,” Cancer, Vol. 60, No. 2, 1987, pp. 170-172. doi:10.1002/1097-0142(19870715)60:2<170::AID-CNCR2820600208>3.0.CO;2-R
[24]	W. C. Mertens, D. T. Shum and J. A. Gilchrist, “Adenocarcinoma of the Eccrine Sweat Gland: Response to both Combination Chemotherapy and Local Field Irradiation,” European Journal of Cancer, Vol. 32A, No. 2, 1996, pp. 372-373. doi:10.1016/0959-8049(95)00525-0
[25]	N. Okada, J. Ota, K. Sato, et al., “Metastasizing Eccrine Sweat Gland Carcinoma, Report of a Case,” Archives of Dermatology, Vol. 120, No. 6, 1984, pp. 768-769. doi:10.1001/archderm. 1984.01650420078021
[26]	C. J. Conley, P. Schau, D. P. Kelsen, et al., “Chemotherapy of Metastatic Sweat Gland Carcinoma. A Retrospective Review,” American Journal of Dermatopathology, Vol. 8, No. 4, 1985, pp. 307-311. doi:10.1097/00000421-198508000-00006
[27]	E. Alssi and R. Caputo, “Syringomatous Carcinoma of the Scalp Presenting as a Slowly Enlarging Patch of Alopecia,” American Journal of Dermatopathology, Vol. 15, 1993, pp. 503-505. doi:10.1097/00000372-199310000-00018
[28]	A. Nishizawa, Y. Nakanishi, Y. Sasajima, et al., “Syringoid Eccrine Carcinoma with Apparently Aggressive Transformation: Case Report and Review of the Literature,” International Journal of Dermatology, Vol. 45, No. 10, 2006, pp. 1218-1221. doi:10.1111/j.1365-4632.2006.02664.x
[29]	R. I. Ceilley and J. Q. Del Rosso, “Current Modalities and New Advances in the Treatment of Basal Cell Carcinoma,” International Journal of Dermatology, Vol. 45, No. 5, 2006, pp. 489-498. doi:10.1111/j.1365-4632.2006.02673.x
[30]	H. Benzel, et al., “Photodynamic Therapy of Superficial Skin Tumors Following Local Application of Delta-Aminolaevulinic Acid,” Advances in Otolaryngology, Vol. 49, 1995, pp. 48-52.
[31]	K. Kalka, H. Merk and H. Mukhtar, “Photodynamic Therapy in Dermatology,” Journal of the American Academy of Dermatology, Vol. 42, No. 3, 2000, pp. 389-413. doi:10.1016/S0190-9622(00)90209-3